Sugammadex Reverses Blockade Faster Than Neostigmine

A meta-analysis of 165 randomized trials links sugammadex to quicker neuromuscular recovery and fewer adverse events than neostigmine.

Updated on Nov. 11, 2026 in Stroke

Bold flat-color vector editorial illustration of two clear glass vials and a steel syringe on a cream background, evoking a clinical drug comparison.
Researchers pooling 165 randomized trials and 19,124 adults found sugammadex reverses moderate neuromuscular blockade faster than neostigmine, with fewer adverse events. AI Illustration. Upload story photo >

A meta-analysis of 165 randomized controlled trials involving 19,124 adults found sugammadex reversed moderate neuromuscular blockade faster than neostigmine. Sugammadex was also associated with a lower risk for at least one adverse event.

Why it matters

Neuromuscular blockade reversal is routine after surgery, and differences in recovery speed and complication rates can shape anesthesia drug choices. The findings come with caveats, as many included trials had unclear or high risk of bias and most did not report primary outcomes.

The analysis pooled 165 trials, with sugammadex 2 mg/kg reversing blockade 10.49 minutes faster than neostigmine across 37 studies and a risk ratio of 0.72 for at least one adverse event across 51 studies. Trial bias ratings were generally unclear or high and most studies did not report primary outcomes.

The players

European Journal of Anaesthesiology

A peer-reviewed clinical journal published by the European Society of Anaesthesiology and Intensive Care, which published the meta-analysis.

The details

Researchers searched databases through December 2025 and included randomized controlled trials comparing sugammadex and neostigmine, each coadministered with atropine or glycopyrrolate, in adults. Risks for selected respiratory and autonomic events were lower with sugammadex, though the trials showed heterogeneity in reversal strategies.

Timeline

  1. December 2025: Literature database search cutoff for included trials.

  2. November 3, 2026: Meta-analysis published online in the European Journal of Anaesthesiology.

Health Landscape

Sugammadex, the first selective relaxant-binding agent approved for reversing rocuronium and vecuronium blockade, has been compared against the long-established cholinesterase inhibitor neostigmine in numerous single trials. This meta-analysis aggregates those trials at scale, shifting the evidence base for a drug that has largely displaced neostigmine in many anesthesia practices.

Patients undergoing surgery with neuromuscular blockade may see their anesthesia team choose between sugammadex and neostigmine based on recovery speed and adverse event profiles. Clinicians weighing these options should consider that many included trials carried unclear or high bias risk.

The takeaway

Faster reversal and fewer adverse events with sugammadex are promising signals, but the strength of the evidence is limited by trial bias and incomplete outcome reporting. Readers should treat the findings as a basis for discussion with their anesthesia team rather than a settled verdict.

Further reading

For broader context on related cardiovascular and neurological outcomes, explore the Stroke section.